Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. - Wikidata - awgldk - TriplyDB

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q45946995

about

Darinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signaling The elements of life and medicines Yin-yang and Zheng: Exported from Chinese medicine.Metabolism, toxicity and anticancer activities of arsenic compounds.Dimethylarsinothioyl glutathione as a metabolite in human multiple myeloma cell lines upon exposure to Darinaparsin Glutathione S-conjugates as prodrugs to target drug-resistant tumors.Multivalency in the inhibition of oxidative protein folding by arsenic(III) species.Pro-Oxidant Activity of Amine-Pyridine-Based Iron Complexes Efficiently Kills Cancer and Cancer Stem-Like Cells NMFBFS: A NMF-Based Feature Selection Method in Identifying Pivotal Clinical Symptoms of Hepatocellular Carcinoma.Determination of multiple human arsenic metabolites employing high performance liquid chromatography inductively coupled plasma mass spectrometry Dual oncogenic and tumor suppressor roles of the promyelocytic leukemia gene in hepatocarcinogenesis associated with hepatitis B virus surface antigen.Anticancer activity of metal complexes: involvement of redox processes.Cellular redox pathways as a therapeutic target in the treatment of cancer.Metal-based drugs that break the rules.The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells.Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.Deciphering the molecular events during arsenic induced transcription signal cascade activation in cellular milieu.Activation of the Nrf2 Signaling Pathway Involving KLF9 Plays a Critical Role in Allicin Resisting Against Arsenic Trioxide-Induced Hepatotoxicity in Rats.

P2860

Q27312382-7E7DA752-88B1-461B-BF7B-02AB61BFD634 Q28649323-1B74D1BA-4ACF-413E-9891-86F2159D4A5A Q30385603-E063F9E1-F851-48CF-823A-1FF2B18FEFEE Q33618916-22F2E04B-22AA-4C97-83E7-EAC9FE840266 Q33637102-918DC5D6-3AAB-4C49-A1D1-8AB0218D4A91 Q34024771-1D952704-1E8E-4435-AF34-571B679EAA7B Q35001166-7AE7869F-4377-4229-BDE7-3F64A50C282E Q35773665-C7D995F6-CC3E-4801-B056-48E156D2822F Q36249939-F75367DD-286A-4FB5-A1D5-A2B5E48E2393 Q36566386-4D948F88-8C9C-498F-A43B-304432137538 Q37317562-6A6C0203-8A84-4A06-9300-606165E4C6A8 Q37833099-83447100-EF71-4181-AE78-937274E740E0 Q37910897-200E722A-27AF-4EF5-9922-D974319E1311 Q38714812-62700C17-6EB5-43DE-A12C-42E90C54635C Q38938902-81C4035B-D7D1-48DC-8895-E9929391B197 Q41069547-48F1FD9A-0D2A-4821-B3E7-82653FE6E941 Q47397630-93400304-23AA-41FB-8051-502B53EB3E8A Q51550506-493F1813-0794-4C88-8F67-8388C0349FC6

P2860

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

http://www.wikidata.org/entity/Q45946995

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

@en

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

@nl

type

label

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

@en

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

@nl

prefLabel

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

@en

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

@nl

P1433

Q45946995-07109E01-4638-4D32-8662-3E91B0B34B00

P1476

Q45946995-4D1B015F-D988-4589-BAC3-700B29F6E52B

P2093

Q45946995-1C870AF8-7C07-4E3B-8C55-AEE6A7AAE1DD

Q45946995-2000441D-49CD-4D53-8A51-C476136C9373

Q45946995-20BD51B9-EDC8-42E3-856E-A2BAD7607CC9

Q45946995-24669C17-7C5D-4E50-85AA-1A393F83BD11

Q45946995-3BE67C52-7A89-44DC-BE1D-F11537F22C7B

Q45946995-91A29A54-E60B-4F64-8DC6-8FC11D83A656

Q45946995-A463113C-BB1C-4CFB-A5AC-F57508341665

Q45946995-B48C31C0-DFD0-45A1-A2AF-5CBD409AB5BD

Q45946995-B8511C6C-3DD8-4F4B-A247-B82DC855AF30

Q45946995-C986DB4B-199D-4954-B091-941ECFD35677

P2860

Q45946995-1F50830D-2466-46E4-B6F4-7E725DB671A4

Q45946995-4836E976-31CA-4E35-BF35-129D9824FD3F

Q45946995-A7E558DA-0055-4379-B9DD-445097288B15

Q45946995-D03A3B94-7534-4D59-AF40-865283047116

Q45946995-DC4FB1F3-F295-4F08-B182-230F21BA35F4

Q45946995-DD62D7BA-CBD0-4F3A-9140-36A2BC8A1C61

Q45946995-DDC07086-B99F-4186-9B50-B3E501F0916C

P2888

Q45946995-1E9AB331-0B6D-4BA1-8E3E-67B8AC3A4830

P304

Q45946995-63175C8B-0F14-43EC-9E3B-4626ACA5F28D

P31

Q45946995-69C73D86-87C5-4234-ACFA-CA9281913D17

P356

Q45946995-9EFDF940-AF77-49C7-8CAA-17A966886FD8

P433

Q45946995-887885BB-489A-44FB-AB13-B27340E21892

P478

Q45946995-F3FB02EE-2939-4B08-BD2F-B0A5F3552961

P50

Q45946995-788FE258-4016-469A-9810-C096AA09D4C0

P577

Q45946995-CD3F94AB-1C51-4AB9-B097-B9E0CA09389E

P6179

Q45946995-0E8E3CC8-87EF-4848-B512-7FC0459E102E

P698

Q45946995-55E5CE77-BFC0-4D89-BEE9-AC9C7B09403D

P356

S10637-009-9286-9

P1433

Investigational New Drugs

P1476

Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.

@en

P2093

Andrew X Zhu

http://www.w3.org/2001/XMLSchema#string

Barry Rosenzweig

http://www.w3.org/2001/XMLSchema#string

Charles Henderson

http://www.w3.org/2001/XMLSchema#string

Giovanni Abbadessa

http://www.w3.org/2001/XMLSchema#string

Haobin Chen

http://www.w3.org/2001/XMLSchema#string

Howard Hochster

http://www.w3.org/2001/XMLSchema#string

Hui Zheng

http://www.w3.org/2001/XMLSchema#string

Jennifer Wu

http://www.w3.org/2001/XMLSchema#string

Jonathan Lewis

http://www.w3.org/2001/XMLSchema#string

Lawrence S Blaszkowsky

http://www.w3.org/2001/XMLSchema#string

P2860

Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.AC) mice.

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.

Effect of arsenic trioxide on human hepatocarcinoma in nude mice.

Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats

Chemical and clinical development of darinaparsin, a novel organic arsenic derivative.

Effects of nickel on DNA methyltransferase activity and genomic DNA methylation levels.

P2888

s10637-009-9286-9

P304

670-676

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-009-9286-9

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1001960219

http://www.w3.org/2001/XMLSchema#string

P698

19565187

http://www.w3.org/2001/XMLSchema#string